Поисковый запрос: (<.>S=МИЕЛОПРОЛИФЕРАТИВНЫЕ БОЛЕЗНИ<.>) |
Общее количество найденных документов : 20
Показаны документы с 1 по 20
|
1.
| Clinical significance of Y chromosome loss in hematologic disease // Genes, Chromosomes and Cancer, 2000. Vol. 27, N 1.-С.11-16
|
2.
| Clinical significance of Y chromosome loss in hematologic disease // Genes, Chromosomes and Cancer, 2000. Vol. 27, N 1.-С.11-16
|
3.
| Effects of in vitro platelet activation on platelet derived nitric oxide production in healthy humans and in chronic myeloproliferative diseases with elevated platelet counts // Platelets, 2003. Vol. 14, N 5.-С.283-286
|
4.
| Effects of in vitro platelet activation on platelet derived nitric oxide production in healthy humans and in chronic myeloproliferative diseases with elevated platelet counts // Platelets, 2003. Vol. 14, N 5.-С.283-286
|
5.
| Relevance of the criteria commonly used to diagnose myeloproliferative disorder in patients with splanchnic vein thrombosis // Brit. J. Haematol., 2005. Vol. 129, N 4.-С.553-560
|
6.
| Relevance of the criteria commonly used to diagnose myeloproliferative disorder in patients with splanchnic vein thrombosis // Brit. J. Haematol., 2005. Vol. 129, N 4.-С.553-560
|
7.
| Relevance of the criteria commonly used to diagnose myeloproliferative disorder in patients with splanchnic vein thrombosis // Brit. J. Haematol., 2005. Vol. 129, N 4.-С.553-560
|
8.
| Manoharan A. Use of whole blood platelet lumi-aggregometry to optimize anti-platelet therapy in patients with chronic myeloproliferative disorders // Amer. J. Hematol., 2006. Vol. 81, N 9.-С.676-683
|
9.
| Inhibition of tissue factor expression by hydroxyurea in polymorphonuclear leukocytes from patients with myeloproliferative disorders: A new effect for an old drug? // J. Thromb. and Haemost., 2006. Vol. 4, N 12.-С.2593-2598
|
10.
| Campbell P.J. Molecular aetiology of the myeloproliferative disorders // Quart. J. Med., 2006. Vol. 99, N 11.-С.786
|
11.
| Lynch S.F. Platelet and endothelial microparticles are elevated in patients with myeloproliferative disorders // Platelets, 2007. Vol. 18, прил. 1.-С.14
|
12.
| Morgan Kelly J. A role for JAK2 mutations in myeloproliferative diseases // Annual Review of Medicine. Vol.59.2008. -Palo Alto (Calif.), 2008.-С.213-222
|
13.
| In vitro platelet aggregation defects in patients with myeloproliferative disorders and high platelet counts: Are they laboratory artefacts? // Platelets, 2009. Vol. 20, N 2.-С.131-134
|
14.
| Evaluation of superoxide dismutase enzyme activity of polymorphonuclear leucocytes, erythrocytes and thrombocytes in patients with chronic myeloproliferative disorders // J. Int. Med. Res., 2009. Vol. 37, N 5.-С.1365-1374
|
15.
| Papadakis Thrombohemorrhagic complications of myeloproliferative disorders // Blood Rev., 2010. Vol. 24, N 6.-С.227-232
|
16.
| Papadakis Thrombohemorrhagic complications of myeloproliferative disorders // Blood Rev., 2010. Vol. 24, N 6.-С.227-232
|
17.
| The use of antiproteolytic mixture fails to modify the abnormal von Willebrand factor pattern in myeloproliferative disease // Folia Haemotol.. -DDR, 1988. Vol. 115, N 6.-С.881-886
|
18.
| Wolf Barbara C. The bone marrow in myeloproliferative and dysmyelopoietic syndromes // Hematol., 1988. Vol. 2, N 4.-С.669-694
|
19.
| Long-term interferon therapy for thrombocytosis in myeloproliferative diseases // Lancet, 1989, N 8639.-С.634-637
|
20.
| Effect of adherent cells on the regulation of BFU-E in patients with myeloproliferative disease // Amer. J. Hematol, 1990. Vol. 33, N 4.-С.225-229
|
|
|
Главная
Назад
"Электронные каталоги и базы данных библиотек СО РАН"